Articles published by Tachyon Therapeutics, Inc.

Tachyon Receives Funding from CIRM for a Phase 1 Clinical Study of TACH101, a First-in-Class KDM4 Inhibitor, in Patients with Advanced Solid Tumors

March 01, 2023

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Announces Financing and Start of Clinical Study of First-in-Class KDM4 Inhibitor for Advanced Cancers

March 01, 2023

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Receives IND Clearance from FDA to Develop Novel KDM4 Inhibitor TACH101 for Advanced Solid Tumors

August 24, 2022

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Presents Preclinical Data on the Company’s Novel KDM4 inhibitor, TACH101, at the 2022 AACR Annual Meeting

April 08, 2022

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Presents New Data Supporting the Development of TACH101, a Novel KDM4 Inhibitor, as a Potential Therapy for Gastrointestinal Cancers at the 2022 ASCO-GI Conference

January 20, 2022

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Presents TACH101 Data at the 2021 AACR-NCI-EORTC Conference

October 08, 2021

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Announces Presentation at the 2021 ESMO Annual Meeting

September 17, 2021

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon and AbCellera Collaborate to Develop Novel Antibody Therapeutic Targeting TGF-β Superfamily Member for the Treatment of Cancer

August 03, 2021

From Tachyon Therapeutics, Inc.

Via Business Wire

Tickers ABCL

Tachyon Announces Presentations at the ASCO Annual Meeting

June 04, 2021

From Tachyon Therapeutics, Inc.

Via Business Wire

Tachyon Presents Promising Preclinical Data on Its First-in-class Pan-KDM4 Epigenetic Regulator, TACH101

April 10, 2021

From Tachyon Therapeutics, Inc.

Via Business Wire

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.